Sugi Predict

Sugi Predict / Compounds / SCHEMBL2584057

SCHEMBL2584057

SCHEMBL2584057

COC(=O)C=Cc1cn([C@@H]2O[C@H](COC(C)=O)C[C@H]2OC(C)=O)c(=O)nc1NO

nearest known ligand 0.33

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 1/20 0.30
▸ THRB P10828 1/20 0.30
▸ SMN1; SMN2 Q16637 1/20 0.30
▸ HIF1A Q16665 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2584871 0.92 LMNA (0.31) LMNATHRBSMN1; SMN2HIF1A
SCHEMBL2584876 0.92 LMNA (0.31) LMNATHRBSMN1; SMN2HIF1A
SCHEMBL2580915 0.91 LMNA (0.32) LMNATHRBSMN1; SMN2HIF1A
SCHEMBL2580911 0.91 LMNA (0.32) LMNATHRBSMN1; SMN2HIF1A
SCHEMBL2584339 0.90 LMNA (0.31) LMNATHRBSMN1; SMN2HIF1A
SCHEMBL2584335 0.90 LMNA (0.31) LMNATHRBSMN1; SMN2HIF1A
SCHEMBL2584305 0.90 LMNA (0.35) LMNATHRBSMN1; SMN2HIF1A
SCHEMBL2584308 0.90 LMNA (0.35) LMNATHRBSMN1; SMN2HIF1A
SCHEMBL2584265 0.89 TLR7 (0.31) LMNATHRBSMN1; SMN2HIF1A
SCHEMBL2578527 0.88 LMNA (0.32) LMNATHRBSMN1; SMN2HIF1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10100076-B2 Modified nucleosides for the treatment of viral infections and abnormal cellular proliferation GILEAD PHARMASSET LLC (US) 2018-10-16 — — US disclosed
US-20140057863-A1 MODIFIED NUCLEOSIDES FOR THE TREATMENT OF VIRAL INFECTIONS AND ABNORMAL CELLULAR PROLIFERATION GILEAD SCIENCES, INC. (US) 2014-02-27 — — US disclosed
US-20110269707-A1 Modified nucleosides for the treatment of viral infections and abnormal cellullar proliferation PHARMASSET, INC. 2011-11-03 — — US disclosed
EP-1411954-B1 MODIFIED NUCLEOSIDES FOR TREATMENT OF VIRAL INFECTIONS AND ABNORMAL CELLULAR PROLIFERATION PHARMASSET INC (US) 2010-12-15 — — EP disclosed
EP-2251015-A1 Modified nucleosides for the treatment of viral infections and abnormal cellular proliferation Pharmasset, Inc. (US) 2010-11-17 — — EP disclosed
US-20030087873-A1 Modified nucleosides for the treatment of viral infections and abnormal cellular proliferation PHARMASSET, INC. 2003-05-08 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140057863-A1 MODIFIED NUCLEOSIDES FOR THE TREATMENT OF VIRAL INFECTIONS AND ABNORMAL CELLULAR PROLIFERATION SLC29A1, PNP, SLC29A2 LMNA 1019/4885THRB 3626/4885SMN1; SMN2 214/4885
US-20110269707-A1 Modified nucleosides for the treatment of viral infections and abnormal cellullar proliferation PNP, ALPP, XDH LMNA 694/4885THRB 4276/4885SMN1; SMN2 676/4885
US-10100076-B2 Modified nucleosides for the treatment of viral infections and abnormal cellular proliferation SLC29A1, SLC29A2, PNP LMNA 821/4885THRB 2955/4885SMN1; SMN2 63/4885
US-20030087873-A1 Modified nucleosides for the treatment of viral infections and abnormal cellular proliferation SLC29A1, PNP, SLC29A2 LMNA 1076/4885THRB 3664/4885SMN1; SMN2 244/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.